Neostigmine compared with

Colistin is completely excreted unchanged in the urine. It is potentially nephrotoxic and ototoxic. Respiratory paralysis due to muscle weakness is rare but cannot be reversed by neostigmine (compared with aminoglycosides). 

Procedure Allelochemical and a compound belonging to natural artificial pesticides and medicinal drugs is preliminary added into the reaction media (see section Add). The difference in cholinesterase activity (measured as shown in sections 15.3) between a control (without the substance added) and the experimental variant is estimated. The results are compared with the effects of the cholinesterase inhibitors neostigmine and physostigmine. 

Compared with neostigmine,2 D.F.P. produced side effects more commonly and these arose in spite of administration of atropine (0-01 gr.) in an attempt to control the gut symptoms. There were no changes in liver, kidney or haemopoietic function ascribed to D.F.P. Asthma was considered a contra-indication to the use of D.F.P. It can thus be seen that D.F.P. in therapeutic dosage is a safe medicament.3... 

The immediate clinical effects and simultaneous changes in blood-cholinesterase activity produced by an intramuscular injection of neostigmine were compared with those which resulted from an intramuscular injection of D.F.P. 

In early study, 99% of 128 patients with myasthenia gravis showed controlled or improved clinical manifestations of the disease. The duration of action of HA lasted 7 6 h, and side effects were minimal compared with neostigmine. ... 

The difference between ACh and neostigmine-type drug lies in the much slower (4 x 107 times) rate of hydrolysis of the carbamoylated enzyme (Fig. 8-10B) compared with the acetylated form (Fig. 8-8C). The clinical duration of action of this drug, during which the AChE is presumably unable to process ACh, is 3-4 hours. 

Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gomez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine a multicenter, randomized, controlled trial. Anesth Analg 2010 110(1) 64-73. 

This serious condition is usually treated with neostigmine. Before the value of this drug had been discovered, ephedrine was the only drug available that in any measure would benefit this disease. How it works is not known. Its action may be related to the observation that in certain nerve-muscle preparations, epinephrine exhibits an anticurare effect. Compared to neostigmine, ephedrine is much less effective and should not be considered the drug of choice. Small doses of 8 to 25 mg several times a day should be used, as large doses may aggravate the disease. 

Although a mechanism to rationally explain their findings is not presented. Green et al have reported data substantiating their previous observations on the influence of cholinesterase inhibitors on the oral absorption of sulfonamides. These workers found that the four-hour plasma levels of sulfacetamide, sulfonilamide and sulfaguanidine were enhanced when the rats were pre-treated with neostigmine as compared to those plasma levels found in the controls. 

Pharmacodynamic actions of PB were studied as early as 1946 by Koster and Koelle. Anticholinesterase activity of PB was about one-fifth of the activity of neostigmine " whereas, the comparative activity reported by Blaschko et al." was about one-tenth. One of the most noticeable differences between neostigmine and pyridostigmine is the inability of the latter compound to produce a direct stimulant action on smooth muscle either in vitro,or in vivof It has been suggested that this may account for the occurrence of fewer unpleasant side effects when pyridostigmine is used clinically." " Foldes and Smith reported maximum inhibition of butyl-cholinesterase with 7 X 10 " M PB at 1 h. 

Comparative studies In a multicenter, randomized, controlled comparison, sugammadex was associated with significantly faster reversal of vecuronium-induced neuromuscular blockade than neostigmine there were no serious or unexpected adverse events [23 ]. 

---